GERN GERON CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—
Leverage & solvency
Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x
Cash quality & payout
Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $237,000 | $596,000 | $1.39M |
| R&D expense | $71.43M | $103.74M | $125.05M | $95.52M | $85.73M |
| SG&A expense | $159.26M | $145.73M | $69.14M | $43.63M | $29.66M |
| Operating income | -$68.58M | -$173.73M | -$193.94M | -$138.55M | -$114.00M |
| Interest expense | $32.66M | $18.50M | $8.31M | $6.88M | $3.74M |
| Pretax income | -$83.42M | -$174.52M | -$181.73M | -$141.90M | — |
| Income tax | $75,000 | $449,000 | $22,000 | — | — |
| Net income | -$83.50M | -$174.57M | -$184.13M | -$141.90M | -$116.11M |
| EBITDA | -$68.11M | -$173.19M | -$193.50M | -$138.26M | -$113.78M |
| EPS (basic) | -0.13 | -0.27 | -0.32 | -0.37 | -0.35 |
| EPS (diluted) | -0.13 | -0.27 | -0.32 | -0.37 | -0.35 |
| Weighted avg. shares (diluted) | 666.66M | 646.03M | 570.65M | 380.78M | 327.63M |
| Balance sheet | |||||
| Cash & equivalents | $77.56M | $79.02M | $70.02M | $56.84M | $34.87M |
| Short-term investments | — | $327.55M | $263.68M | $115.90M | $148.85M |
| Receivables | $36.99M | $35.95M | — | — | — |
| Inventory | $116.64M | $38.71M | — | — | — |
| Current assets | $520.27M | $490.99M | $341.35M | $180.25M | $187.21M |
| PP&E, net | $884,000 | $1.31M | $1.18M | $793,000 | $650,000 |
| Total assets | $570.54M | $593.78M | $394.08M | $190.57M | $226.03M |
| Current liabilities | $111.54M | $88.30M | $108.07M | $76.69M | $45.52M |
| Short-term debt | — | $0 | $46.89M | $20.95M | — |
| Long-term debt | $119.55M | $118.48M | $35.05M | $30.21M | $49.83M |
| Total debt | $119.55M | $118.48M | $81.94M | $51.16M | $49.83M |
| Total liabilities | $344.67M | $313.46M | $146.13M | $110.58M | $99.62M |
| Shareholders' equity | $225.87M | $280.32M | $247.95M | $80.00M | $126.42M |
| Net debt | $41.99M | $39.46M | $11.92M | -$5.69M | $14.96M |
| Shares outstanding | 639.86M | 606.39M | 544.91M | 390.26M | 323.73M |
| Cash flow statement | |||||
| Operating cash flow | -$111.04M | -$218.62M | -$167.74M | -$127.38M | -$95.56M |
| Capital expenditure | — | $680,000 | $830,000 | $431,000 | $207,000 |
| Free cash flow | — | -$219.30M | -$168.57M | -$127.81M | -$95.76M |
| Investing cash flow | $107.25M | -$106.00M | -$180.32M | $62.07M | $71.95M |
| Financing cash flow | $2.27M | $334.37M | $362.02M | $87.26M | $48.56M |
| Depreciation & amortization | $474,000 | $546,000 | $442,000 | $288,000 | $215,000 |
| Stock-based compensation | $26.66M | $31.18M | $18.53M | $8.00M | $8.08M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.